M Ventures

About

Portfolio · 14

lizo.AI

Artificial intelligence–based operating system for Real Estate Investments

1 round $4.0M committed Latest: 2025-09

Medisafe

Medication Management Platform

2 rounds $14.5M committed Latest: 2024-12

Genopore

Semiconductor Protein Detector

2 rounds $2.7M committed Latest: 2024-05

Nucleai

Spatial Biology Software Platform for Precision Medicine

Led ★ 1 round $14.0M committed Latest: 2024-04

Sentaur Biosciences

Pioneering Precision Therapeutics for Senescence Driven Diseases

3 rounds Latest: 2023-07

PxE Computational Imaging

Advanced 3D Imaging Technology

Led ★ 2 rounds $6.5M committed Latest: 2023-03

Metabomed

Target-inhibiting Anticancer Drugs

4 rounds $30.5M committed Latest: 2022-04

Wiliot

Battery-free Bluetooth Tags

3 rounds $235.0M committed Latest: 2021-07

Immunorizon

T-and NK-cell Engagers for Cancer Therapy

3 rounds Latest: 2020-02

PillTracker

Real-time Medication Tracking Platform

1 round Latest: 2019-12

Pantheon Bioscience

Platform of Bacterial Defense Mechanism

2 rounds $2.1M committed Latest: 2019-06

Feelit Technologies

Nanomaterial-based Sensing Solutions for IoT Applications

Led ★ 1 round Latest: 2019-03

ARTSaVIT

Cancer Apoptosis Technology

2 rounds Latest: 2018-03

ChanBio

Biopharmaceuticals for Treatment of Multiple Sclerosis

1 round Latest: 2013-11

Investment activity

2 portfolio exits on record.

Q&A

What is M Ventures' primary investment focus and strategy?

M Ventures is the strategic corporate venture arm of Merck KGaA of Darmstadt, Germany. It operates as an evergreen fund, focusing on Biotechnology and Technology in alignment with Merck's strategic interests in Healthcare, Life Sciences, Electronics, Frontier Tech, and Sustainability.

What is M Ventures' geographic focus for investments?

M Ventures is active in the Israeli ecosystem, investing in Israeli companies within its fields of interest.

Does M Ventures provide any additional support to its portfolio companies beyond financing?

Yes, M Ventures holds an incubator facility in Israel, offering seed financing and access to dedicated laboratories within Merck's Israel-based biopharma R&D center for its portfolio companies.

Can you name a recent exit for M Ventures?

In February 2023, M Ventures saw an exit with Immunorizon, which was acquired by Purple Biotech for $100M.

What are M Ventures' typical investment stages?

M Ventures primarily invests in Seed and Pre-Seed stage companies.

Which sectors does M Ventures concentrate its investments in?

M Ventures shows a strong concentration in Health Tech & Life Sciences, with 11 portfolio companies, and Industrial Technologies, with 4 portfolio companies.

Who leads M Ventures' Israeli Bio-Incubator?

Noga Yerushalmi serves as the Head of M Ventures' Israeli Bio-Incubator.

Can you name a notable recent investment by M Ventures?

M Ventures participated in a Seed round for lizo.AI in April 2024, which raised $4M for its AI-based operating system for Real Estate Investments.

What is one of M Ventures' larger portfolio companies by funding raised?

Wiliot, a company developing battery-free Bluetooth tags, has raised $344M and is a portfolio company of M Ventures.